Discover 1,922 paid clinical trials in Irving, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,922
Active & Responsive
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
for
Primary Sjogren's Disease
Location: Euless TX, Irving TX, Fort Worth TX, Dallas TX,
Sponsor: Vor Biopharma
Sex: All
Age: 18 - 70+
Code: NCT07404865
Phase3, Recruiting
Active & Responsive
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
for
Rheumatoid Arthritis
Location: Colleyville TX, Tomball TX, Lake Charles LA, Houston TX,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07137598
Phase2, Recruiting
Active & Responsive
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Get alerts for new trials in your area by subscribing now
Active & Responsive
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
for
Breast Neoplasms, Breast Cancer
Location: Dallas TX, Houston TX, Nashville TN, Skokie IL,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06797635
Phase2, Recruiting
Active & Responsive
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies